MarketCapExport financials
AbCellera Biologics (ABCL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AbCellera Biologics Balance Sheet 2025-2011 | ABCL
Brief overview of AbCellera Biologics's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
The asset base was stable: the change from $1.3 billion to $1.4 billion does not indicate a material increase in scale.
Liabilities expanded faster than the asset base, +33.2% versus +2.9%. Debt-service capacity deserves attention.
Internal capital represents 71.3% of the balance sheet, previously 77.8%. This is a strong capital position.
Net debt is $14.7 million, or 0.02x of equity. This is a conservative debt position.
The cash reserve occupies 9.5% of the balance sheet, previously 38%. It is one marker of short-term resilience.
The accumulated result is -$29.5 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
AbCellera Biologics's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
14.7 M | -91 M | -55.9 M | -304 M | -461 M | -592 M | -3.72 M | -7 M | - | - | - | - | - | - | - |
Long Term Debt |
137 M | 60.7 M | 71.2 M | 76.7 M | 36.4 M | 2.2 M | 1.36 M | 911 K | - | - | - | - | - | - | - |
Long Term Debt Current |
5.82 M | 4.62 M | 6.16 M | 5.58 M | 3.65 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
326 M | 228 M | 217 M | 189 M | 172 M | 71.5 M | 5.34 M | 3.45 M | - | - | - | - | - | - | - |
Total Current Liabilities |
64.3 M | 76.6 M | 119 M | 118 M | 121 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
390 M | 304 M | 336 M | 308 M | 293 M | 175 M | 13.2 M | 9.88 M | - | - | - | - | - | - | - |
Deferred Revenue |
13.5 M | 13.5 M | 19 M | 21.6 M | 7.54 M | 7.53 M | 3.24 M | 2.33 M | - | - | - | - | - | - | - |
Retained Earnings |
-29.5 M | 117 M | 280 M | 426 M | 268 M | 114 M | -4.72 M | -2.5 M | - | - | - | - | - | - | - |
Total Assets |
1.36 B | 1.36 B | 1.49 B | 1.54 B | 1.32 B | 1.01 B | 23.5 M | 21.5 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
129 M | 156 M | 133 M | 387 M | 501 M | 594 M | - | - | - | - | - | - | - | - | - |
Book Value |
967 M | 1.06 B | 1.15 B | 1.23 B | 1.03 B | 831 M | 10.3 M | 11.6 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
967 M | 1.06 B | 1.15 B | 1.23 B | 1.03 B | 831 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet AbCellera Biologics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
130 M | 134 M | 137 M | 137 M | 63.2 M | 60.7 M | 66.3 M | 66.5 M | 68.1 M | 71.2 M | 75.2 M | 78.1 M | 77.3 M | 76.7 M | 71.6 M | 32.8 M | 36.4 M | 36.4 M | 27.3 M | 31 M | 17 M | 3.72 M | 3.72 M | 3.72 M | 3.72 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
358 M | 322 M | 323 M | 328 M | 246 M | 228 M | 235 M | 231 M | 228 M | 217 M | 219 M | 223 M | 200 M | 189 M | 196 M | 160 M | 171 M | 172 M | 170 M | 114 M | 83 M | 71.5 M | 71.5 M | 71.5 M | 71.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
412 M | 369 M | 392 M | 395 M | 321 M | 304 M | 315 M | 302 M | 333 M | 336 M | 329 M | 342 M | 289 M | 308 M | 302 M | 381 M | 385 M | 293 M | 219 M | 184 M | 171 M | 175 M | 175 M | 175 M | 175 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
20.7 M | 7.74 M | 15.7 M | 16.9 M | 18.8 M | 13.5 M | 5.58 M | 6.4 M | 10.6 M | 19 M | 17.5 M | 8.54 M | 11.8 M | 21.6 M | 6.82 M | 4.62 M | 9.19 M | 7.54 M | 6.17 M | 10.6 M | 11.3 M | 6.59 M | 6.59 M | 6.59 M | 6.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-128 M | -72.6 M | -20.5 M | 36.6 M | 71.3 M | 117 M | 151 M | 202 M | 239 M | 280 M | 327 M | 356 M | 386 M | 426 M | 456 M | 429 M | 436 M | 268 M | 208 M | 229 M | 231 M | 114 M | 114 M | 114 M | 114 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.31 B | 1.31 B | 1.36 B | 1.4 B | 1.34 B | 1.36 B | 1.39 B | 1.41 B | 1.46 B | 1.49 B | 1.51 B | 1.54 B | 1.5 B | 1.54 B | 1.55 B | 1.59 B | 1.59 B | 1.32 B | 1.17 B | 1.15 B | 1.13 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
120 M | 77.1 M | 83.2 M | 92.4 M | 159 M | 156 M | 152 M | 173 M | 149 M | 133 M | 197 M | 205 M | 218 M | 387 M | 397 M | 816 M | 571 M | 476 M | 518 M | 793 M | 686 M | 594 M | 594 M | 594 M | 594 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
896 M | 938 M | 964 M | 1.01 B | 1.02 B | 1.06 B | 1.08 B | 1.11 B | 1.13 B | 1.15 B | 1.18 B | 1.19 B | 1.21 B | 1.23 B | 1.25 B | 1.21 B | 1.21 B | 1.03 B | 953 M | 968 M | 957 M | 831 M | 831 M | 831 M | 831 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
896 M | 938 M | 964 M | 1.01 B | 1.02 B | 1.06 B | 1.08 B | 1.11 B | 1.13 B | 1.15 B | 1.18 B | 1.19 B | 1.21 B | 1.23 B | 1.25 B | 1.21 B | 1.21 B | 1.03 B | 953 M | 968 M | 957 M | 831 M | 831 M | 831 M | 831 M | 10.3 M | - | - | - | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of AbCellera Biologics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Russia
Canada
Schweiz
